MNTA—That level of detail hasn't been disclosed, but I would be shocked if the phase-3 trial for M923 did not incorporate the FDA's latest thinking on the number of switches.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”